An Edinburgh angel investment syndicate has leveraged £17.9m in the first half of 2026, providing backing to promising early-stage companies.
Archangels, which is headquartered in the capital and was recently named Angel Group of the Year at the UK Business Angels Association awards, secured the funding to support high-growth scale-ups across the technology and life science sectors.
The total capital includes £7.2m invested directly by the syndicate’s members, alongside £10.7m of co-investment secured from partner investors.
Locally, the syndicate supported major funding rounds for two University of Edinburgh spin-outs. Biocaptiva raised £1.58m to commercialise its patented msX platform, which extracts cell-free DNA directly from whole blood without centrifuges, improving liquid biopsy sample preparation for cancer research and diagnostics.
Archangels also participated in a £6.2m Series A round for Bioliberty, another University of Edinburgh spin-out. The round, led by the Scottish National Investment Bank, will support local product development and manufacturing, alongside commercial expansion in the US for its AI-powered soft-robotic wearable rehabilitation platform.
The investment activity follows a record year for Scotland’s early-stage investment market, which saw a total of £1.15bn raised in 2025. Established in 1992, Archangels is recognised as the world’s longest continuously operating business angel syndicate.
David Ovens, Joint Managing Director at Archangels, said: “The first half of 2026 has been another active period for Archangels, with the syndicate backing some genuinely exceptional companies.
“Biocaptiva and Bioliberty are each addressing significant global challenges, and the quality of co-investment we’ve been able to attract alongside our members reflects just how compelling these opportunities are to the wider investor community.
“Scotland’s early-stage ecosystem continues to punch well above its weight, and while the macroeconomic backdrop remains uncertain, the pipeline of innovative companies coming through gives us real confidence, going into the second half of the year.
“Archangels has been backing Scotland’s best founders for over 30 years, and the ambition and quality we’re seeing today is as strong as it’s ever been.
“To be named Angel Group of the Year by our industry peers is a huge accolade and is testament to the strength of our board, team and syndicate members, who consistently invest £10m-£15m of their own money each year into Scotland’s most promising technology and life sciences companies, as well as providing access to their networks and experience.”
- This article or a part of it is provided by the news agency Deadline News Limited and published here with permission.
- Contact Deadline News Limited if you would like to use any or all of this article.
